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Abstract
Background: Procalcitonin (PCT) is a valuable prognostic biomarker in human sepsis that is predictive of organ
dysfunction, septic shock and mortality. Data on PCT in dogs is limited. This study aimed to investigate the prognostic
value of baseline and serial PCT measurements in dogs with sepsis and to determine the association between PCT and
sepsis severity and the presence of organ dysfunction. PCT concentrations were measured in citrated plasma samples
collected from 53 dogs with sepsis at the time of admission (T0, n = 53) and at 24 h (T1, n = 35) and 48 h (T2, n = 30)
post-admission using a commercial ELISA. Dogs were classified by sepsis severity (sepsis without organ dysfunction;
severe sepsis; septic shock) and outcome (survivors; non-survivors). Organ dysfunctions were recorded at T0 and during
hospitalization, and the APPLEfast score calculated at T0. Healthy dogs (n = 12) were used as controls.
Results: There were 18 septic dogs without organ dysfunction, 24 dogs with severe sepsis and 11 with septic shock.
Baseline PCT concentrations were significantly greater in dogs with sepsis compared to healthy controls (P < 0.0001),
and in dogs with septic shock compared to dogs without cardiovascular compromise (P = 0.01). Baseline PCT was
significantly correlated with organ dysfunction (P = 0.003). Declining PCT concentrations were documented in survivors
at T1 and T2 compared to PCT at T0 (P = 0.0006), and PCT clearance at 24 h was significantly higher in survivors (n = 38)
compared to non-survivors (n = 15) (P = 0.037). Canine APPLEfast score was not predictive of sepsis severity, the
development of MODS or outcome.
Conclusion: In dogs with sepsis, PCT concentrations at hospital admissions are predictive of organ dysfunction and
septic shock. Serial procalcitonin monitoring may offer valuable prognostic information in canine sepsis, wherein early
decreases in PCT concentrations are associated with survival.
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Introduction
Sepsis, the life-threatening organ dysfunction caused by
a dysregulated host response to infection [1], is a leading
cause of death in critically ill human and veterinary
patients [2, 3]. Early diagnosis and prompt recognition
of disease severity are crucial to the rapid administration
of antimicrobials [4, 5], timely hemodynamic resuscita-
tion [6–8], and to the individualization of care [9]. Thus,
there is considerable interest in the development of
biomarkers for individual prognostication [10–12], and
for the prediction of sepsis-related complications, such
as multiple organ dysfunction syndrome (MODS) and
septic shock [13–15].
Procalcitonin (PCT), the prohormone of calcitonin,
has emerged as a promising sepsis biomarker in humans
[16]. Procalcitonin is released ubiquitously in response
to microbial toxins and specific pro-inflammatory medi-
ators, and its concentrations rise early after the exposure
to an infectious stimulus [17–19]. Several trials and
meta-analyses have highlighted the clinical value of PCT
for diagnosis of bacterial sepsis in critically ill humans
[17]. In addition, PCT has been demonstrated to reliably
assess prognosis and to chart the severity of sepsis [20],
wherein higher circulating PCT concentrations are
present in humans with MODS compared to those with-
out organ dysfunction [21]. Furthermore, although the
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prognostic significance of a single PCT measurement re-
mains unclear, persistently increased PCT concentrations
during hospitalization are associated with increased
mortality in humans with severe sepsis, septic shock and
MODS [22]. As such, the concept of PCT clearance
(PCT-c) may provide superior prognostic value and en-
hance the study of PCT kinetics [23, 24]. The potential
value of monitoring PCT kinetics was demonstrated by
a recent multicenter study in humans that identified
patients who, by day 4, had failed to clear PCT by more
than 80% from baseline had substantially increased mor-
tality [16]. Conversely, circulating PCT concentrations
are decreased (and PCT-c is increased) during the
recovery phase, when infection control is achieved [16].
As such, monitoring PCT kinetics may aid both the
initiation of antimicrobials [25], and the discontinu-
ation of antimicrobials, thereby limiting unnecessary
prescribing and reducing the duration of antimicrobial
therapy [26–28]. As a result, PCT monitoring is now
advocated to guide antimicrobial stewardship in
several human systemic infections [29, 30].
Few studies in the veterinary literature have evaluated
the ability of biomarkers to predict sepsis severity and
MODS occurrence in dogs [31, 32]. In addition, despite
the considerable interest in PCT in human medicine, to
date few studies have investigated the role of procalcito-
nin in dogs. In part, this may be the result of the previ-
ous lack of an assay for canine PCT protein [33]. Those
studies that do exist suggest that in dogs the PCT gene
is expressed in extra-thyroidal tissues in a variety of con-
ditions associated with systemic inflammation [34–36].
Plasma procalcitonin concentrations are significantly in-
creased in dogs with sepsis, but there is some overlap in
the plasma PCT concentrations found in healthy dogs
and those with sepsis (unpublished observations). A pre-
liminary study of PCT mRNA expression in leukocytes
in dogs with sepsis suggests that PCT gene expression
parallels the course of the underlying disease, however,
suggesting that plasma PCT measurements might be of
value in monitoring disease progression and the re-
sponse to therapy in dogs with sepsis [35].
The aims of the present study were therefore: 1) to
evaluate associations between plasma procalcitonin
concentrations and illness severity, organ dysfunction
and outcome in a population of dogs with sepsis; 2) to
evaluate the prognostic value of procalcitonin clearance
by serial procalcitonin measurements in a population of
dogs with sepsis.
Materials and methods
Animals
A database of stored plasma samples collected at hospital
admission from dogs at-risk for MODS was searched for
dogs with sepsis. All dogs were prospectively enrolled
between 02/2015 and 04/2017 in a study investigating
MODS. That study was approved by the local Institutional
Animal Care and Use Committee (University of Bologna
DL 26/2014, Project 846) and was undertaken with writ-
ten informed client consent. Respective primary clinicians
determined all aspects of patient management.
Dogs were diagnosed with sepsis if at least 2/4 SIRS
criteria were satisfied, as previously described [37], and
an infection was confirmed by means of cytology, micro-
biology, histopathology or real-time polymerase chain
reaction. Specifically, in cases of pyometra, the diagnosis
was made on the basis of pre-operative ultrasonographic
findings, gross evaluation of the uterus during ovariohys-
terectomy and the results of histopathology [38]. The
diagnosis of parvoviral enteritis was based on positive
real-time polymerase chain reaction analyses of fecal
samples, as previously described [39].
Dogs were eligible for inclusion in the present study if
they were hospitalized in the intensive care unit (ICU)
for at least 12 h and if an aliquot of citrated plasma col-
lected upon hospital admission was available. All citrate
plasma samples were stored frozen at − 80 °C from col-
lection until analysis. Where requested by the attending
clinicians, serial blood samples were collected 24 h (T1)
and 48 h (T2) after hospital admission. When samples
were collected per clinician requests, aliquots of citrated
plasma were also frozen at − 80 °C to enable subsequent
analyses.
Twelve healthy privately-owned blood donor dogs
were enrolled as controls (University of Bologna,
Project 581) with informed owner consent. These
dogs were eligible if they had no history or evidence
of recent or chronic medical conditions and had not
received any medication, except for routine preventa-
tive healthcare, within the preceding 3 months. Dogs
were classified healthy on the basis of history, phys-
ical examinations, and complete blood count and
serum chemistry results.
Data collection
As part of the parent MODS study various patient
parameters were recorded at the time of hospital ad-
mission as follows: medical history including comor-
bidities and prior treatment, physical examination
findings, therapies administered. At hospital admission
(T0), non-invasive blood pressure measurement,1 and
pulse oximetry,2 were performed. Blood gas and elec-
trolyte analyses and blood lactate measurement were
performed using a point-of-care analyzer.3 Complete
blood counts and serum chemistry analyses were
performed using automated analyzers.4,5 Coagulation
assays were performed on citrated plasma using a
benchtop automated analyzer.6 Patient data were used
to calculate the shortened Acute Patient Physiologic
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and Laboratory Evaluation (APPLEfast) score as previ-
ously described [40].
Illness severity and outcome classification
Dogs were classified as suffering from sepsis without
organ dysfunction, severe sepsis (sepsis with organ
dysfunction) or septic shock based on the Society of
Critical Care Medicine consensus definitions from 2001
[41]. Organ dysfunction was deemed present if it was
noted at hospital admission or occurred during the
course of hospital stay. This organ dysfunction was re-
quired to involve an organ system other than that af-
fected by the septic focus e.g. a patient with
pneumonia would not be classified as having severe
sepsis if only the respiratory system was abnormal.
Organ dysfunction criteria were adapted from avail-
able canine literature (Table 1). Where appropriate,
cutoff values for specific clinicopathologic variables
e.g. serum creatinine concentration were based on the
upper bound of the reference intervals of the institution
laboratory. The number of dysfunctional organs at hos-
pital admission and the maximum number of dysfunc-
tional organs (ODmax) during hospital stay were also
recorded. Outcome was recorded as survival to hospital
discharge, death, or euthanasia for disease severity.
Procalcitonin measurements
Plasma concentrations of PCT were measured on all dogs
at T0, and on all available samples from T1 and T2 using
a commercial ELISA kit.7 Procalcitonin concentrations
were measured as a batch at Cornell University. Samples
from Bologna were transported to Cornell on dry ice by
overnight courier. All samples were frozen on arrival and
were stored at − 80 °C prior to analysis. Procalcitonin is
reportedly stable for prolonged periods at − 80 °C [42].
Procalcitonin clearance (expressed as percent) at 24 and
48 h was calculated according to eq. 1, as previously re-
ported [23, 24].
PCT clearance PCT−cð Þ at 24 h
¼ PCTT0–PCTT1ð Þ=PCTT0  100 ð1Þ
Statistical methods.
Prior to test selection, data were assessed for normality
by assessment of histograms, calculation of skewness
and kurtosis and with the D’Agostino Pearson test.
Descriptive statistics were calculated as appropriate.
Most variables were not normally distributed and hence
continuous variables are reported as median (min-max)
and were compared using non-parametric tests. The
Mann Whitney U test and the Kruskal-Wallis test with
Dunn’s post-hoc adjustment for multiple comparisons
were used to compare continuous variables between
groups. Categorical variables were compared using
Fisher’s exact test. Scatterplots and calculation of
Spearman’s coefficients were used to assess correlations
between continuous variables. All analyses were per-
formed using commercial software.8 Alpha was set at 0.05.
Results
Study population
Fifty-three dogs with sepsis were enrolled. There were
22 intact female dogs, 5 spayed female dogs, 22 intact
male dogs and 4 castrated male dogs. The median age
was 7y (0.08–15.5). The median bodyweight was 18.5 kg
(3.7–55.7). All dogs met at least 2/4 SIRS criteria [37].
The median rectal temperature on presentation was
39.0 °C (36.3–41.0) [102.2 °F (97.3–105.8)], the median
heart rate was 135 bpm (60–240), the median respiratory
rate was 32 rpm (12–108) and the median leukocyte
count was 12.8 × 103/μL (0.37–76.2). The median
APPLEfast score was 24 (14–33) and the median duration
of hospital stay was 5d (1–20). The causes of sepsis were
parvoviral enteritis (n = 15), septic peritonitis (n = 14),
pyometra (n = 13), necrotizing fasciitis (n = 5); bacterial
prostatitis (n = 2) and perineal abscess, pyelonephritis,
Table 1 Organ dysfunction criteria adapted for use in the present study
Organ system Organ dysfunction criterion Reference
Cardiovascular Systolic blood pressure < 90 mmHg despite adequate fluid resuscitation [51]
Hemostatic PT > 7.5 s OR
aPTT > 16.5 s OR
Platelet count < 160 × 109/L (< 160 × 103/μL)
[3, 46]
Hepatic Increase in serum bilirubin > 6.0 μmoL/L (> 0.35 mg/dL)
(in the absence of hemolysis or biliary obstruction)
[3, 46]
Renal Serum creatinine (sCr) > 119.3 μmoL/L (> 1.35 mg/dL) OR
Increase in sCr of > 26.5 μmoL/L (≥ 0.3 mg/dL) from baseline OR
Oliguria (urine output < 1 mL/kg/h over 6 h)
[52]
Respiratory SpO2 < 95% on room air OR
SpO2 / FiO2 < 315 on supplemental oxygen OR
PaO2 / FiO2 < 400 mmHg on supplemental oxygen
[3, 46, 53]
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pneumonia and pyothorax (all n = 1). Comorbidities
were identified in 21 patients (40%), and included
inflammatory-bowel disease, chronic kidney disease,
chronic hepatopathy, heart disease, neoplasia, urinary
tract obstruction and intestinal parasitism. Thirty dogs
received antimicrobials in the 7 days preceding hospital
admission, while 2 dogs were receiving immunosuppres-
sive therapy at the time of presentation. Thirty-eight
dogs (72%) survived to hospital discharge, while 15
(28%) dogs were non-survivors. Ten of the 15 non-
survivors were euthanized. No dog was euthanized due
to financial limitations.
Eighteen dogs (34%) had sepsis without organ dys-
function, 24 dogs (45%) had severe sepsis and 11 dogs
(21%) showed signs of circulatory failure requiring va-
sopressors and were classified with septic shock. In
the first 24 h of ICU stay kidney and hepatic dysfunc-
tion were the most commonly documented n = 14
(26%) and n = 13 (24%) respectively, followed by car-
diovascular n = 10 (19%), hemostatic n = 9 (17%) and
respiratory n = 3 (6%). An increase in the number of
dysfunctional organs was noted in 17 dogs (35%). It
was not possible to determine progression of organ
dysfunction in 5 dogs, due to death or euthanasia
within 24 h of ICU admission. The median ODmax
was 1 (0–4). Descriptive statistics for the clinicopath-
ologic variables evaluated in septic dogs are reported
in Table 2. The healthy control dog population (n = 12)
consisted of 5 intact male dogs, 5 intact female dogs and 2
female spayed dogs. The median age was 4y (2–7). The
median bodyweight was 29 kg (22–42.4).
Baseline procalcitonin concentrations
Upon presentation, the median PCT concentration in the
dogs with sepsis was significantly greater than in healthy
controls 103.0 pg/mL (15.4–470.2) versus 41.6 pg/mL
(21.5–88.7) (P < 0.001) (Fig. 1). The baseline (T0) PCT
concentrations were significantly greater in dogs with
septic shock compared to dogs with sepsis but without
cardiovascular compromise 243.1 pg/mL (56.7–369.8) vs.
77 pg/mL (18.2–470.2) (P = 0.005) (Fig. 2). There was no
significant difference in the PCT concentrations at T0
between survivors and non-survivors 87.64 pg/mL
(15.39–470.2) vs. 150.2 pg/mL (26.34–369.8) (P = 0.18)
(Fig. 3a). Procalcitonin concentration at T0 was positively
correlated with ODmax (rs 0.4, P = 0.003) and negatively
correlated with leukocyte count (rs − 0.49, P = 0.0002)
(Additional file 1: Figure S1A). There was no significant
difference between the PCT concentrations of dogs with
versus without comorbidities (P = 0.99), or between dogs
that had received antimicrobials prior to presentation
compared to those that did not (P = 0.59). There was no
significant correlation between PCT concentration and
APPLEfast score (P = 0.26).
Serial procalcitonin evaluation
Thirty-eight dogs (72%) underwent serial blood sampling
during the first 48 h of ICU stay: there were 35 samples
available for PCT measurement at T1, and 30 samples
available at T2. In the whole population, baseline (T0)
PCT concentrations 103.0 pg/mL (15.39–470.2) were
significantly greater than PCT concentrations at T1
45.34 pg/mL (2.02–432.7) (P = 0.002) and at T2
42.79 pg/mL (3.9–559.3) (P < 0.001) (Additional file 2:
Figure S2). Survivors had significantly lower PCT
concentrations at T1 42.5 pg/mL (7.5–432.7) (P < 0.01),
and T2 41.9 pg/mL (3.9–559.3) (P = 0.001) compared to
respective PCT concentrations at presentation (Fig. 4).
There were no significant differences in plasma PCT
concentrations between baseline and T1 or T2 in in
non-survivors (P = 0.06) (Fig. 4). Procalcitonin clearance
was significantly higher in survivors compared to
non-survivors 44% (− 38 to 82) versus 1% (− 39 to 62)
(P = 0.037) at 24 h but not at 48 h (P = 0.59).
Clinicopathologic data
Dogs with septic shock had significantly lower white
blood cell counts compared to dogs without cardiovas-
cular compromise 4.5 × 103/μL (0.37–29.7) versus 15.1 ×
103/μL (0.38–76.2) (P = 0.007). Non-survivors had a sig-
nificantly shorter duration of hospital stay compared to
survivors 5d (2–20) versus 3d (1–11) (P = 0.049). The
number of dysfunctional organs was significantly higher
in non-survivors compared to survivors both at the time
of admission 0 (0–2) versus 1 (1–4) and during ICU stay
2 (1–4) versus 1 (0–3) (both P < 0.0001). At the time of
Table 2 Descriptive statistics for selected clinicopathologic
variables measured in dogs with sepsis (n = 53). Data are
presented as median (min-max)
Variable (units) Institution
reference intervals
Dogs with sepsis
(n = 53)
Procalcitonin (pg/mL) – 103 (15.4–470.2)
APPLEfast score – 24 (14–33)
Leukocytes (×109/L) 6–17 12.8 (0.37–76.2)
Platelets (×109/L) 160–500 269 (30–602)
Hematocrit (%) 37–55 42.5 (23.7–68.5)
Total protein (g/L) 56–79 60 (27–82)
Albumin (g/L) 28–37 23 (14–35)
Creatinine (μmol/L) 57.5–119.3 75.1 (23.0–686.9)
Bilirubin (μmol/L) 1.2–5.8 3.9 (1.2–50.3)
Glucose (mmol/L) 3.9–6.9 5.4 (0.6–48.3)
Lactate (mmoL/L) 0–2 2.0 (0.5–8.2)
PT (s) 5.0–7.5 6.9 (5–15.7)
aPTT (s) 8.0–16.5 13.1 (9.3–47.1)
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presentation, the frequency of hepatic and of cardiovas-
cular dysfunction was greater in non-survivors
compared to survivors 53% versus 13% (P = 0.004) and
47% versus 8% (P = 0.003) respectively. Absolute
frequencies of renal, hemostatic and respiratory dysfunc-
tion upon admission were higher in non-survivors, but
these differences were not statistically significant. The
APPLEfast score at the time of presentation was not
significantly different between dogs with distinct sepsis
severity classifications (P = 0.783), or between survivors
and non-survivors (P = 0.071) (Fig. 3b).
Discussion
In the present study dogs with sepsis had significantly
greater plasma PCT concentrations than healthy
control dogs. Based on the previous veterinary litera-
ture [35, 36], and our own observations, this result
was expected and suggests that PCT is a potential
biomarker for sepsis in dogs. There was some overlap
between the concentrations of PCT in septic and
healthy dogs, however, which may limit the utility of
PCT measurement for the diagnosis of sepsis. The
degree of overlap noted in the present study is com-
parable to our previous observations (unpublished
data). As such, canine acute phase proteins, such as
C-reactive protein, may be better suited to the
identification of systemic inflammation than PCT
[43]. The majority of the dogs with comparable
concentrations to those of healthy dogs had sepsis
without organ dysfunction, suggesting that PCT may
be more specific for cases of severe sepsis and septic
shock. Other data from the present study suggest that
the magnitude of PCT alteration may be related to
sepsis severity and organ dysfunction. Plasma PCT
concentrations were significantly higher in dogs with
septic shock compared to dogs without cardiovascular
compromise.
The PCT concentrations in the dogs with sepsis were
quite variable (Fig. 1), which accounts for some of the
overlap between the healthy controls and the dogs with
sepsis. The large range of PCT concentrations in the
dogs with sepsis was likely due to variation in illness se-
verity in these dogs. This is supported by the significant
difference identified between the PCT concentrations in
dogs with sepsis and in those dogs with septic shock
(Fig. 2). In humans, the diagnostic accuracy of circulat-
ing PCT for sepsis varies with illness severity, wherein
PCT is more accurate for identification of severe sepsis
and septic shock [17]. This suggests that PCT may be
optimally used to assess illness severity in patients that
already have a working diagnosis of sepsis. Likewise,
Fig. 1 Dogs with sepsis have significantly greater plasma
procalcitonin concentrations than healthy controls. A box and
whisker plot comparing the plasma procalcitonin (PCT)
concentrations from 12 healthy control dogs and 53 dogs with
sepsis. The central lines represent the median, the boundaries of the
boxes represent the interquartile range and the whiskers represent
the minimum and maximum values. Dogs with sepsis had
significantly greater plasma concentrations of PCT compared to
healthy controls (P < 0.001) by Mann-Whitney U test
Fig. 2 Plasma procalcitonin concentrations are significantly greater
in dogs with septic shock compared to dogs without cardiovascular
compromise. A box and whisker plot comparing the baseline (T0)
plasma procalcitonin (PCT) concentrations in dogs with sepsis but
without shock (n = 42) and dogs with septic shock (n = 11). The
central lines represent the median, the boundaries of the boxes
represent the interquartile range and the whiskers represent the
minimum and maximum values. Dogs with septic shock had
significantly greater plasma concentrations of PCT compared to
dogs without septic shock (P = 0.005) by Mann-Whitney U test
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PCT measurements might aid with the prediction of
impending septic shock or the development of organ
dysfunction.
In the present study, PCT concentrations at the time
of presentation were not prognostic. This finding may
result from an inherent limitation in the discriminant
ability of PCT in canine sepsis. It might also be due to
the bias of early therapeutic interventions that can posi-
tively influence a patient’s outcome. Similar findings
have been reported for several acute phase proteins in
dogs, wherein markedly abnormal baseline values do not
necessarily herald a poor prognosis [44, 45]. The present
study suggests that baseline PCT concentrations are
correlated with the development and with the degree of
organ dysfunction and with the presence of septic shock.
These abnormalities themselves are associated with non-
survival in dogs with sepsis, however [3, 46]. As such, it
may be that the lack of association between baseline
PCT and outcome here relates to limited sample size
and a low illness severity in the overall population. It
may be that the optimal use for a baseline PCT meas-
urement is the identification of patients at risk for later
complications. This would be valuable information for
clinicians, who might be able to adjust or intensify
therapy, to provide additional monitoring for high-risk
patients and to prompt early screening to identify organ
dysfunction.
The present study found no correlation between base-
line PCT concentration and the APPLEfast score. This sug-
gests that these two indices provide different information
about dogs with sepsis. Although the prognostic value of
the APPLEfast score has been reported in previous studies
of critically ill dogs [40, 47–49], it was not predictive of
outcome in the present population, nor was it associated
a b
Fig. 3 Illness severity and plasma procalcitonin (PCT) concentrations at presentation are not significantly associated with outcome. Box and
whisker plots comparing baseline APPLEfast scores (a) and plasma procalcitonin concentrations (b) between survivors (n = 38) and non-survivors
(n = 15). The central lines represent the median, the boundaries of the boxes represent the interquartile range and the whiskers represent the
minimum and maximum values. No significant difference was documented by Mann-Whitney U test for APPLEfast (P = 0.071) or PCT concentration
(P = 0.185) between the two groups
Fig. 4 In dogs with sepsis, procalcitonin (PCT) clearance over the
first 48 h of hospitalization is significantly greater in survivors
than in non-survivors. Box and whisker plots comparing serial
plasma PCT concentrations at baseline (T0), + 24 h (T1) and +
48 h (T2) in survivors and non-survivors. The central lines
represent the median, the boxes represent the interquartile range and
the whiskers represent the minimum and maximum values. Survivors
showed a significant decline in PCT concentrations from baseline to T1
(P < 0.01) and T2 (P = 0.001) by Kruskal-Wallis with Dunn’s post-hoc
multiple comparisons test. No statistically significant difference in serial
PCT concentrations was detected for non-survivors between any of the
time points (overall Kruskal-Wallis P = 0.06)
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with the occurrence of MODS. Individual illness severity
scores are not universally predictive, however, and a lack
of prognostic value has been reported in other clinical set-
tings [48]. It may be that combinations of illness-severity
scores and biomarkers or combinations of biomarkers
may be needed to accurately prognosticate complex
clinical syndromes like sepsis [49, 50].
In the present study, a significant negative correlation
was documented between baseline PCT and leukocyte
count, which may point to PCT being an early marker
of disease severity in canine sepsis. Dogs in the present
study with septic shock had higher PCT concentrations
and lower leukocyte counts. Most of the dogs with septic
shock in the present study (7/11 dogs) were diagnosed
with parvoviral enteritis. This may have accounted for
the lower leukocyte counts identified in this sub-group.
Interestingly, no differences in PCT concentrations was
detected between groups classified by sepsis cause in the
present study (data not shown).
The present study suggests that evaluation of PCT
kinetics may be a promising prognostic tool for dogs
with sepsis. Significantly decreased PCT concentra-
tions from baseline and a high PCT clearance at 24 h
were documented in survivors. This suggests the early
downregulation of PCT expression in patients reco-
vering from sepsis. In contrast, PCT clearance was
low in non-survivors, suggesting that persistently in-
creased PCT concentrations should alert clinicians to
the possibility of treatment failures, novel infections
or persistent organ dysfunction. This parallels the
situation in people, where a lack of reduction in PCT
concentrations from baseline is a strong predictor of
mortality in sepsis [20], and specific cut-off values
have been validated to aid prognostication in indivi-
duals [16].
The present study adds to our understanding of the
links between biomarkers and MODS and to the associ-
ation of MODS with outcome in canine sepsis. The num-
ber of dysfunctional organs both at the time of admission
and during hospital stay, as well as the magnitude of organ
dysfunction, were significantly higher in non-survivors.
These results corroborate the findings of two recent stud-
ies in critically ill dogs documenting a strong relationship
between the severity of organ dysfunction and mortality
[3, 46], and further advocate for systematic and frequent
screening for MODS in critically ill dogs.
The present study may have some limitations.
Although septic dogs were enrolled prospectively for the
parent MODS study, PCT analyses were performed
retrospectively on the citrated plasma samples available.
Thus, complete and consistent serial evaluation of PCT
concentrations was not possible for the whole study
population. In addition, the relatively low number of
non-survivors, as well as the occurrence of early death
or euthanasia (< 24 h of ICU stay) may have diminished
statistical power, leading to an underestimation of the
prognostic significance of PCT clearance. Although eu-
thanasia was performed only after clinical judgement of
moribund condition or end-stage disease, its impact
should be taken into account as a potential source of
bias. Finally, the study population was heterogeneous in
terms of onset and causes of sepsis, treatment protocols
and illness severity. Studies focusing on selected septic
diseases and on more severely affected septic patients
exclusively (e.g. severe sepsis and septic shock) might
better enable investigation of the utility of PCT mea-
surements [17, 23]. The results of the present study are
likely to too preliminary to be used to guide alterations
to the diagnostic or management plans for individual
dogs with sepsis. Confirmation of these findings in other
populations will be necessary before clinicians should
consider incorporating PCT measurement into their
decision-making. Finally, the ELISA method used to
measure canine PCT in the present study is currently
only accessible in a research setting and a point-of-care
test is not currently available. The routine availability of
PCT measurement would be necessary to make PCT
guided therapies possible in veterinary medicine.
Conclusions
In conclusion, the present study suggests that PCT may
be a promising prognostic biomarker in canine sepsis,
specifically that baseline procalcitonin concentrations
are associated with the development of MODS and with
septic shock, while PCT clearance in the first 24 h is as-
sociated with survival and recovery from sepsis. Further
prospective studies are necessary to confirm the prog-
nostic significance of serial procalcitonin measurement
in distinct populations over longer time-intervals. Future
studies might also compare the diagnostic and prognos-
tic utility of PCT with that of other biomarkers in order
that biomarker guided therapeutic strategies may
become possible.
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Additional files
Additional file 1: Figure S1. Scatterplots and Spearman’s coefficients
assessing correlations between baseline procalcitonin (PCT)
concentrations and the maximum number of organ dysfunction (ODmax),
leukocyte count and the APPLEfast score. Plasma PCT concentrations are
significantly and positively correlated with ODmax and inversely correlated
with leukocyte count (rs 0.400, P = 0.003; rs − 0.488, P = 0.0002
respectively). There was no significant correlation between plasma PCT
and the APPLEfast score (rs 0.126; P = 0.2601). (EPS 139 kb)
Additional file 2: Figure S2. In hospitalized dogs with sepsis managed
with clinician-driven standard care, there is a significant clearance of
baseline procalcitonin (PCT) concentrations over time. Box and whisker
plots comparing serial plasma PCT concentrations at hospital admission
(T0), and + 24 h (T1) and + 48 h (T2) in 53 dogs with sepsis. The central
lines represent the median, the boxes represent the interquartile range
and the whiskers represent the minimum and maximum values. There
are significant decreases in PCT concentrations from T0 to T1 (P = 0.002)
and T2 (P < 0.001) by Kruskal-Wallis with Dunn’s post-hoc multiple com-
parisons test. (EPS 69 kb)
Abbreviations
APPLE: acute patient physiologic and laboratory evaluation; ELISA: enzyme-
linked immunosorbent assay; ICU: intensive care unit; MODS: multiple organ
dysfunction system; PCT: procalcitonin; SIRS: systemic inflammatory response
syndrome
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